How are lifetime polytobacco users different than current cigarette-only users? Results from a Canadian young adult population

How are lifetime polytobacco users different than current cigarette-only users? Results from a Canadian young adult population
复制标题

DOI:
10.1016/j.addbeh.2009.06.009
复制
发表时间:
2009-12-01
影响因子:
4.4
通讯作者:
O'Hegarty, Michelle
O'Hegarty, Michelle
中科院分区:
医学2区
文献类型:
--
作者:
Bombard, Jennifer M.;Pederson, Linda L.;O'Hegarty, Michelle

文献摘要

被引文献

相似文献

目前吸烟与曾经使用过其他烟草产品(终生使用多种烟草)的情况进行检查很重要,因为吸烟者可能面临更大的非法药物使用、尼古丁成瘾和不良健康后果的风险。我们确定了终生使用多种烟草的估计和模式,并进行了多变量分析,以确定与加拿大年轻人样本中使用多种烟草相关的人口统计、家庭和朋友、心理社会和生活方式因素。目前吸烟的总患病率为36.3%,仅当前吸烟的患病率为10.1%,终生使用多种烟草的患病率为26.2%。在复合烟草使用者中,目前吸烟和曾经使用雪茄的频率最高(67.2%)。对于男性,最终的模型包括人口统计、家庭和朋友以及生活方式因素。对于女性,最终的模型还包括心理社会因素。非法药物使用是男性终生使用多种烟草的最显著预测因素。当比较终生吸烟者和目前仅吸烟者时,我们发现了性别差异,特别是男性终生吸烟者更有可能使用毒品和酒精。针对个别物质的干预措施应考虑处理组合使用问题。爱思唯尔有限公司出版。
Current cigarette smoking combined with ever use of other tobacco products (lifetime polytobacco use) is important to examine as users may be at greater risk for illicit drug use, nicotine addiction, and adverse health outcomes. We determined estimates and patterns of lifetime polytobacco use and conducted multivariable analyses to determine demographic, family and friend, psychosocial, and lifestyle factors associated with use among a sample of Canadian young adults. Overall prevalence was 36.3% for current cigarette use; 10.1% for current cigarette use only and 26.2% for lifetime polytobacco use. Among polytobacco users, current cigarette use and ever cigar use was most frequent (67.2%). For males, the final model contained demographic, family and friends, and lifestyle factors. For females, the final model also included psychosocial factors. Illicit drug use was the strongest significant predictor for lifetime polytobacco use among males. We found gender specific differences when comparing lifetime polytobacco users to current cigarette-only users, in particular; male lifetime polytobacco users were more likely to use drugs and alcohol. interventions focusing on individual substances should consider addressing combinations of use. Published by Elsevier Ltd.